Fundraising Fox
/People
Sign in

Johannes Fruehauf

Investor

General Partner at Mission Biocapital · Board director at Quralis

Cambridge

Writes $500K checks · typically $1.5M

Find your path to Johannes

195 people in our graph can introduce you to Johannes.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Ulrik B. Nielsen to introduce you to Johannes

You →Ulrik · together at Volnay Therapeutics (2023–2026) →Johannes

Ask Jamie Chen to introduce you to Johannes

You →Jamie · 2 people · together at Pandion Therapeutics →Johannes

Ask Sam Okafor to introduce you to Johannes

You →Sam · 4 people · together at Quralis →Johannes

Sign up to find every way you can get introduced to Johannes

  • Your email: the people you already email who know Johannes
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Johannes
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

About

General Partner in the Cambridge office who sources, diligences, and leads new investments; board roles at Arkuda, QurAlis, Vaxess, and Sentien. Co-founder and President of LabCentral and CEO of BioLabs. Trained in medicine in Germany and France with a doctorate from the University of Heidelberg.

Contact· self-published, not guessed

Invests in

AgTechBiotechFoodTechHealthtechMedical DevicesNew Materials

Board director at Quralis

Intro paths

→

In turn, Johannes can intro founders to Quralis's investors below.

Quralis's investors · 16

ALS Investment FundAmsterdam · since 2023Amgen VenturesThousand Oaks · $1M – $3M checks · since 2023Dementia Discovery FundLondon · since 2023Diamond Edge VenturesSan Francisco · since 2018Dolby Family VenturesSan Francisco · since 2023Droia VenturesLuxembourg · $540K checks · since 2025EQT Life SciencesLuxembourg · $11M – $66M checks · since 2023InkefAmsterdam · since 2023MC Healthcare VenturesCambridgeMission Bay CapitalSan Francisco · since 2023Mission BiocapitalSan Francisco · $500K checks · since 2025Mitsui Global InvestmentMenlo Park · $500K – $10M checks · since 2023Polaris PartnersBoston · $500K – $5M checks · since 2025Sanofi VenturesCambridge · $5M checks · since 2023SV Health InvestorsLondon · $1M – $20M checksSynconaLondon · since 2022

Co-founders at Quralis

KEKevin Eggan
Kevin EgganCo-founder
R
RoetCo-founder
W
WoolfCo-founder
KRKasper Roet
Kasper RoetDirector, Executive Officer, Promoter

Experience

  1. LabCentralFounder and Chairmancurrent2025 — presentKendall Square, Cambridge
  2. LabCentralFounder and President/CEO2012 — 2025
  3. Mission BioCapitalGeneral Partner, Co-Foundercurrent2011 — presentGreater Boston Area
  4. BioLabsPresident & CEO, Foundercurrent2009 — present
  5. Zag BioInvestor and Board Membercurrent2023 — present
  6. Volnay TherapeuticsFounder, President, Member of the Boardcurrent2022 — presentBoston and Europe
  7. QurAlisBoard Membercurrent2018 — presentCambridge, MA
  8. Vaxess TechnologiesBoard Member2016 — 2025
  9. Arkuda TherapeuticsInvestor and Board Member2019 — 2025Watertown, Massachusetts, United States
  10. Tidal TherapeuticsFounding Investor and Board Director2018 — 2021Cambridge, MA
  11. TotientFounding Investor and Observer2018 — 2021Cambridge, Massachusetts, United States
  12. Sentien Biotechnologies, Inc.Board Director2016 — 2021Cambridge, MA
  13. Pandion TherapeuticsInvestor and Board Observer2018 — 2020Cambridge MA
  14. Mitokinin IncBoard Director2017 — 2018NYC/SF
  15. ViThera PharmaceuticalsFounder, Chairman2011 — 2015Cambridge, MA
  16. Aura BiosciencesVice President, Research and Development2009 — 2011
  17. Cequent Pharmaceuticals (now Marina Biotech NASDAQ: MRNA)Vice President, Medical Affairs (Consultant)2009 — 2010
  18. Cequent Pharmaceuticals (now Marina Biotech NASDAQ: MRNA)Vice President, Research2006 — 2010Cambridge, MA
  19. Cequent Pharmaceuticals (now Marina Biotech NASDAQ: MRNA)Director, Preclinical and Clinical Development2006 — 2007
  20. BIDMC/Harvard Medical SchoolSenior Research Fellow2004 — 2007
  21. BIDMC/Harvard Medical SchoolPostdoctoral Fellow2002 — 2004
  22. University Hospital Mannheim (Germany)Residency in OB/GYN1999 — 2002
  23. Klinikum Hanau (Germany)Physician - Internal Medicine (18 months)1997 — 1999

Skills & more

Drug Discovery62Biotechnology95Lifesciences46Clinical Development18Cancer8Clinical Trials13Technology Transfer42In Vivo10Assay Development14Drug Delivery6Start-ups37Entrepreneurship21
+12 moreMolecular BiologyVenture CapitalHealthcareDrug DevelopmentBiochemistryCommercializationPharmaceuticsBiopharmaceuticalsPharmaceutical IndustryINDStrategyCell Biology

Languages English · French · German

From Johannes's professional profile.

Deals · 1

Vaxess Technologies, Inc.Board seat

via Mission Biocapital · filed Mar 2021 · $2M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

MitokininQuralis

Sources: SEC Form D filings · curated public sources.

Colleagues at Mission Biocapital

Cassidy Blundell
Partner at Mission Biocapital
Chaya Patel
Principal at Mission Biocapital
Chris Carlin
Chief Operations Officer and Chief Compliance Officer at Mission Biocapital
Clay Rowland
Investment Associate at Mission Biocapital
Douglas Crawford
Managing General Partner at Mission Biocapital
Jennifer Griffin
Partner at Mission Biocapital
Josephine Brysting
Investment Analyst at Mission Biocapital
Linda Eng
Director of Operations, Bay Area at Mission Biocapital

Network3

Cassidy Blundell
Partner at Mission Biocapital
Chaya Patel
Principal at Mission Biocapital
Douglas Crawford
Managing General Partner at Mission Biocapital

Investors connected to Johannes in public investor directories — a warm-intro map.

Frequently asked questions

Who is Johannes Fruehauf?
General Partner in the Cambridge office who sources, diligences, and leads new investments; board roles at Arkuda, QurAlis, Vaxess, and Sentien. Co-founder and President of LabCentral and CEO of BioLabs. Trained in medicine in Germany and France with a doctorate from the University of Heidelberg.
Where does Johannes Fruehauf work?
Johannes Fruehauf is General Partner at Mission Biocapital and Board director at Quralis.
What does Johannes Fruehauf invest in?
Johannes Fruehauf invests in AgTech, Biotech, FoodTech, Healthtech, Medical Devices, New Materials.
What check size does Johannes Fruehauf write?
Johannes Fruehauf typically writes checks of $500K.
What boards does Johannes Fruehauf sit on?
Johannes Fruehauf holds tracked board seats at Mitokinin, Quralis, Vaxess Technologies, Inc..
What companies has Johannes Fruehauf invested in?
Investments tracked here include Quralis, Sentien Biotechnologies, Sentieon Inc., Zag Bio.
Where did Johannes Fruehauf go to school?
Johannes Fruehauf studied at Harvard Medical School (Postdoc, Molecular Biology); SLP Boston 2012 (Fellow, Entrepreneurship/Entrepreneurial Studies); Goethe University Frankfurt (MD, Medicine).

Same school

Shared employers